It is classified as grade IV by the World Health Organization (WHO) classification of tumors of the central nervous system and is diagnosed based on histological parameters like tumor necrosis and, since the current update (2016 WHO Classification of Tumors of the Central Nervous System), on additional molecular features like the status of isocitrate dehydrogenase (IDH). The gene discussed is IDH3A; the disease is central nervous system cancer.